ZURA BIO LTD (ZURA) Stock Fundamental Analysis

NASDAQ:ZURA • KYG9TY5A1016

6.21 USD
-0.05 (-0.8%)
At close: Feb 12, 2026
6.21 USD
0 (0%)
After Hours: 2/12/2026, 8:22:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ZURA scores 2 out of 10 in our fundamental rating. ZURA was compared to 523 industry peers in the Biotechnology industry. ZURA has a great financial health rating, but its profitability evaluates not so good. ZURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ZURA had negative earnings in the past year.
  • In the past year ZURA has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ZURA reported negative net income in multiple years.
  • ZURA had a negative operating cash flow in each of the past 5 years.
ZURA Yearly Net Income VS EBIT VS OCF VS FCFZURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -43.44%, ZURA is in line with its industry, outperforming 56.41% of the companies in the same industry.
  • ZURA has a better Return On Equity (-57.76%) than 61.95% of its industry peers.
Industry RankSector Rank
ROA -43.44%
ROE -57.76%
ROIC N/A
ROA(3y)-30.48%
ROA(5y)N/A
ROE(3y)-48.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZURA Yearly ROA, ROE, ROICZURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ZURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZURA Yearly Profit, Operating, Gross MarginsZURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ZURA has been increased compared to 1 year ago.
  • ZURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZURA Yearly Shares OutstandingZURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ZURA Yearly Total Debt VS Total AssetsZURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • ZURA has an Altman-Z score of 4.14. This indicates that ZURA is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ZURA (4.14) is better than 70.94% of its industry peers.
  • There is no outstanding debt for ZURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.14
ROIC/WACCN/A
WACCN/A
ZURA Yearly LT Debt VS Equity VS FCFZURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 5.58 indicates that ZURA has no problem at all paying its short term obligations.
  • With a Current ratio value of 5.58, ZURA perfoms like the industry average, outperforming 58.51% of the companies in the same industry.
  • ZURA has a Quick Ratio of 5.58. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 5.58, ZURA is doing good in the industry, outperforming 60.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.58
Quick Ratio 5.58
ZURA Yearly Current Assets VS Current LiabilitesZURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • ZURA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.69%.
EPS 1Y (TTM)-4.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -12.61% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-40.02%
EPS Next 2Y-19.89%
EPS Next 3Y-12.61%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZURA Yearly Revenue VS EstimatesZURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 10M 20M 30M
ZURA Yearly EPS VS EstimatesZURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZURA. In the last year negative earnings were reported.
  • Also next year ZURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZURA Price Earnings VS Forward Price EarningsZURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZURA Per share dataZURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as ZURA's earnings are expected to decrease with -12.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.89%
EPS Next 3Y-12.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ZURA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZURA BIO LTD

NASDAQ:ZURA (2/12/2026, 8:22:28 PM)

After market: 6.21 0 (0%)

6.21

-0.05 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners60.57%
Inst Owner ChangeN/A
Ins Owners7.49%
Ins Owner Change0%
Market Cap403.77M
Revenue(TTM)N/A
Net Income(TTM)-62.52M
Analysts86.15
Price Target16.32 (162.8%)
Short Float %6.41%
Short Ratio4.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.99%
Min EPS beat(2)-13.48%
Max EPS beat(2)11.5%
EPS beat(4)2
Avg EPS beat(4)4.34%
Min EPS beat(4)-17.47%
Max EPS beat(4)36.82%
EPS beat(8)4
Avg EPS beat(8)1.27%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.73
P/tB 3.73
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.44%
ROE -57.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.48%
ROA(5y)N/A
ROE(3y)-48.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 361.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.58
Quick Ratio 5.58
Altman-Z 4.14
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
EPS Next Y-40.02%
EPS Next 2Y-19.89%
EPS Next 3Y-12.61%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-179.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-379.86%
OCF growth 3YN/A
OCF growth 5YN/A

ZURA BIO LTD / ZURA FAQ

Can you provide the ChartMill fundamental rating for ZURA BIO LTD?

ChartMill assigns a fundamental rating of 2 / 10 to ZURA.


What is the valuation status of ZURA BIO LTD (ZURA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZURA BIO LTD (ZURA). This can be considered as Overvalued.


Can you provide the profitability details for ZURA BIO LTD?

ZURA BIO LTD (ZURA) has a profitability rating of 1 / 10.


What is the financial health of ZURA BIO LTD (ZURA) stock?

The financial health rating of ZURA BIO LTD (ZURA) is 7 / 10.